SCHEMBL3147740

SCHEMBL3147740

COC(=O)[C@@H](Cc1ccc(Cl)cc1)NC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
YAP1 P46937 2/20 0.54
ALDH1A1 P00352 3/20 0.50
MAPT P10636 3/20 0.50
MAPK1 P28482 3/20 0.50
HTT P42858 2/20 0.50
STS P08842 2/20 0.50
NPC1 O15118 1/20 0.50
RAB9A P51151 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
NPSR1 Q6W5P4 5/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
MEN1 O00255 5/20 0.47
KMT2A Q03164 5/20 0.47
POLB P06746 1/20 0.47
GPR55 Q9Y2T6 1/20 0.47
CNR1 P21554 1/20 0.47
LMNA P02545 1/20 0.46
GAA P10253 1/20 0.46
USP2 O75604 1/20 0.46
HPGD P15428 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL655029 1.00 YAP1 (0.54) YAP1ALDH1A1MAPTMAPK1HTT
SCHEMBL654273 0.94 YAP1 (0.50) YAP1ALDH1A1MAPTMAPK1HTT
SCHEMBL3154278 0.90 YAP1 (0.54) YAP1ALDH1A1MAPTMAPK1HTT
SCHEMBL3149509 0.84 CACNA1B (0.46) L3MBTL1KMT2ALMNAGAA
SCHEMBL3157224 0.84 CACNA1B (0.46) L3MBTL1KMT2ALMNAGAA
SCHEMBL651575 0.84 HTT (0.51) ALDH1A1MAPTMAPK1HTTSTS
SCHEMBL652849 0.80 HTT (0.57) ALDH1A1MAPTMAPK1HTTSTS
SCHEMBL5197183 0.79 MEN1 (0.42) YAP1ALDH1A1MAPTMAPK1HTT
SCHEMBL654137 0.79 LMNA (0.60) ALDH1A1MAPTMAPK1HTTSTS
SCHEMBL5449383 0.78 MEN1 (0.44) ALDH1A1MAPTMAPK1HTTSTS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1773796-B1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI AVENTIS (FR) 2010-03-03 EP disclosed
CN-101039941-A Aminopiperidine derivatives, their preparation and use as melanocortin receptor agonists SANOFI AVENTIS (FR) 2007-09-19 CN disclosed
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-08-16 US disclosed
US-20070149562-A1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI-AVENTIS (FR) 2007-06-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070149562-A1 OXOPIPERIDINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF MC5R, MC4R, OPRD1 YAP1 443/4885ALDH1A1 338/4885MAPT 2661/4885
US-20070191364-A1 AMINOPIPERIDINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF MC4R, MC5R, TAAR5 YAP1 807/4885ALDH1A1 344/4885MAPT 2200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.